 SEOUL, Souh Korea, July 19, 2021 PRNewswire -- Lunit, a leading AI startup in AI-powered cancer solutions, today announced a strategic investment of 26 million from Guardant Health, Inc. Nasdaq: GH, a leading precision oncology company. The deal, which includes the investment made by Guardant Health and also a groundbreaking collaboration between a liquid biopsy company and a medical AI startup, is intended to help reshape and innovate the precision oncology landscape. 